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Background:  Endomyocardial biopsy (EMB) remains the gold-standard for diagnosis of acute cellular rejection (ACR) after heart transplantation 
(HTx). Repeated EMB poses unique risks in children including use of general anesthesia and loss of vascular access. Thus we studied 
echocardiographic left ventricular Myocardial Performance Index (LVMPI) in pediatric HTx patients.
Objective: To compare LVMPI during biopsy-proven rejection (ISHLT ≥2R) to biopsy-proven no rejection baseline in children after HTx.
Methods:  We identified 33 children with grade ≥2R ACR more than 60 days post-HTx and reviewed 2D / Doppler echocardiogram studies on 
these patients at 3 different times: biopsy-proven ACR (grade ≥2R), the immediate preceding EMB showing no ACR (≤1R), and the immediate follow-
up EMB showing no ACR. LVMPI, the sum of the isovolumetric contraction and relaxation times divided by the left ventricular ejection time, was 
determined by 2 independent reviewers on each study using spectral doppler tracings.
Results:  At the time of ACR, patients were an average of 35 months post-HTx. There was a significant difference in LVMPI at the time of ACR vs. 
the immediate preceding EMB (0.54 ± 0.14 vs. 0.43 ± 0.11; p<0.001), but no significant difference in shortening fraction (37.4 ± 6.2% vs. 38.4 
± 5.3%; p=0.2) or ejection fraction (57.6% ± 10.9% vs. 56.8% ± 9.6%; p=0.49). Following ACR, LVMPI returned to 0.42 ± 0.11. An LVMPI of 0.46 
was 79% sensitive and 63% specific for ACR grade ≥2R with area under the ROC curve of 0.72. An increase in LVMPI of 22% from baseline was 88% 
sensitive and 79% specific for ACR ≥2R with area under the ROC curve of 0.86. Bland-Altman analysis showed excellent agreement between the 2 
reviewers (mean difference -0.011 with limits of agreement -0.146 to 0.169).
Conclusions:  LVMPI increases at the time of EMB proven ACR with subsequent improvement to baseline upon EMB proven resolution of ACR. 
Within each patient, serial measurement of LVMPI may provide a more useful adjunct than adoption of a set ‘cut-point’ for predicting ACR in children 
after HTx.
